U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
Status:
Active, not recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate safety and antitumor activity of U3-1402 in two parts:
Dose Escalation and Dose Expansion.
In Dose Escalation, U3-1402 will be evaluated in participants with metastatic or unresectable
NSCLC with epidermal growth factor receptor (EGFR) activating mutation after disease
progression during/after EGFR tyrosine kinase inhibitor (TKI) therapy.
In Dose Expansion, U3-1402 will be evaluated in participants with metastatic or unresectable
NSCLC with EGFR activating mutation or squamous or non-squamous NSCLC (ie, without
EGFR-activating mutations) with disease progression during/after systemic treatment for
locally advanced or metastatic disease.